Your browser doesn't support javascript.
loading
Effects of recombinant human interleukin 11 and granulocyte colony stimulating factor in mobilization for autologous peripheral blood stem cell transplantation / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 345-349, 2008.
Artículo en Chino | WPRIM | ID: wpr-253322
ABSTRACT
This study was aimed to evaluate the effects of recombinant human interleukin 11 (rhIL-11) and recombinant human granulocyte colony stimulating factor (rhG-CSF) in mobilization for autologous peripheral blood stem cell transplantation (APBSCT). 16 patients with non-Hodgkin's lymphoma or acute myeloblastic leukemia were given myelosuppressive chemotherapy, then were mobilized by using rhG-CSF 5 microg/(kg.d) for median 5.5 days and rhIL-11 50 microg/(kg.d) for median 4 days (experimental group) or rhG-CSF 5 microg/(kg.d) alone for median 5.5 days (control group). After mobilizing, the peripheral blood leucocyte and platelet counts, total mononuclear cells, CD34+ cells and CFU-GM counts in PBSC collection, and amount of apheresed platelet transfusion were assayed. The results showed that the peripheral blood leucocyte and platelet counts, total mononuclear cell, CD34+ cell and CFU-GM counts in PBSC collection were no significant difference between two groups (p>0.05). After APBSCT, the median time for neutrophil count>or=0.5x10(9)/L and the median time for platelet count>or=20x10(9)/L were 10.5 and 11.5 days in experimental group, while were 13 and 13 days in control group, respectively. The median amount of apheresed platelet transfusion was 3.5 unit in experimental group and 5 unit in control group. Data were significantly different between two groups (p<0.05). The adverse reactions of mobilization were mild fever, fatigue, symptoms like as common cold, poor appetite, dizziness, muscular soreness in experimental group, but only mild fever in control. These symptoms were well tolerated and overcome with drug withdrawal. It is concluded that the regimen of rhIL-11 in combination with rhG-CSF after myelosuppressive chemotherapy to mobilize PBSC is efficient and safe with rapid hematologic reconstitution and less platelet transfusions after APBSCT were used.
Asunto(s)
Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Terapéutica / Trasplante Autólogo / Linfoma no Hodgkin / Proteínas Recombinantes / Leucemia Mieloide Aguda / Factor Estimulante de Colonias de Granulocitos / Interleucina-11 / Movilización de Célula Madre Hematopoyética / Trasplante de Células Madre de Sangre Periférica / Métodos Límite: Adolescente / Adulto / Femenino / Humanos / Masculino Idioma: Chino Revista: Journal of Experimental Hematology Año: 2008 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Terapéutica / Trasplante Autólogo / Linfoma no Hodgkin / Proteínas Recombinantes / Leucemia Mieloide Aguda / Factor Estimulante de Colonias de Granulocitos / Interleucina-11 / Movilización de Célula Madre Hematopoyética / Trasplante de Células Madre de Sangre Periférica / Métodos Límite: Adolescente / Adulto / Femenino / Humanos / Masculino Idioma: Chino Revista: Journal of Experimental Hematology Año: 2008 Tipo del documento: Artículo